Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · ZeroStack Corp. (ZSTK)

ZeroStack agrees to sell Phatebo GmbH to New Horizon Pharma for €2.15 million

Neutral Impact 2 of 5 m&a

ZeroStack Corp. agreed on November 3, 2026 to sell all outstanding shares of its wholly owned subsidiary Phatebo GmbH to New Horizon Pharma B.V. for an aggregate price of €2,150,000. Closing depends on German foreign direct investment clearance and other agreed closing conditions, so the sale is not yet complete. The filing does not state the effect of the sale on ZeroStack's financial results.

Key points

  • Buyer: New Horizon Pharma B.V.; the company owns 100% of Phatebo GmbH before the sale.
  • Aggregate purchase price: €2,150,000.
  • Closing requires German foreign direct investment clearance and other closing conditions in the Purchase Agreement.
  • Purchase Agreement dated November 3, 2026 is filed as Exhibit 10.1.

The filing

CompanyZeroStack Corp. (ZSTK)
Form8-K, current report
Filed with the SECNov 9, 2026, 4:11 PM ET
Accession number0001062993-26-005837

Items reported: 1.01 Material Definitive Agreement

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 7:16 PM ET, from this filing only.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.